UPDATE 1-Teva to discontinue study for chronic headache treatment

June 15 (Reuters) - Israel's Teva Pharmaceutical Inc said on Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis showed that the drug was unlikely to meet the study's main goal.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.